Compare · ACIU vs ANVS
ACIU vs ANVS
Side-by-side comparison of AC Immune SA (ACIU) and Annovis Bio Inc. (ANVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACIU and ANVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ACIU is the larger of the two at $212.7M, about 4.6x ANVS ($46.6M).
- ANVS has been more active in the news (16 items in the past 4 weeks vs 3 for ACIU).
- ANVS has more recent analyst coverage (5 ratings vs 2 for ACIU).
- Company
- AC Immune SA
- Annovis Bio Inc.
- Price
- -
- -
- Market cap
- $212.7M
- $46.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- 2020
- News (4w)
- 3
- 16
- Recent ratings
- 2
- 5
AC Immune SA
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Annovis Bio Inc.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
Latest ACIU
- AC Immune to Present at Jefferies Global Healthcare Conference 2026
- SEC Form 6-K filed by AC Immune SA
- AC Immune Third Quarter 2026 Financial and Corporate Update
- Amendment: SEC Form 3/A filed by AC Immune SA
- SEC Form 3 filed by AC Immune SA
- SEC Form 6-K filed by AC Immune SA
- SEC Form 6-K filed by AC Immune SA
- AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
- SEC Form 6-K filed by AC Immune SA
- SEC Form 6-K filed by AC Immune SA
Latest ANVS
- SEC Form 10-Q filed by Annovis Bio Inc.
- Annovis Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Annovis Provides Corporate Updates and Reports Third Quarter 2026 Financial Results
- Annovis Bio Granted U.S. Patent Covering New Crystalline Form of Buntanetap
- Annovis Announces Closing of $21.0 Million Public Offering with 24% Contribution from the Board Chairman
- Director Hoffman Michael B bought $5,000,000 worth of shares (5,000,000 units at $1.00), increasing direct ownership by 149% to 8,364,883 units (SEC Form 4)
- Annovis Bio Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits
- SEC Form 424B5 filed by Annovis Bio Inc.
- Annovis Announces Pricing of $21.0 Million Public Offering
- SEC Form 424B5 filed by Annovis Bio Inc.